EA201992687A1 - NEWcastle Disease VIRUSES AND THEIR APPLICATION - Google Patents

NEWcastle Disease VIRUSES AND THEIR APPLICATION

Info

Publication number
EA201992687A1
EA201992687A1 EA201992687A EA201992687A EA201992687A1 EA 201992687 A1 EA201992687 A1 EA 201992687A1 EA 201992687 A EA201992687 A EA 201992687A EA 201992687 A EA201992687 A EA 201992687A EA 201992687 A1 EA201992687 A1 EA 201992687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
newcastle disease
chimeric
viruses
disease viruses
application
Prior art date
Application number
EA201992687A
Other languages
Russian (ru)
Inventor
Питер Пейлиз
Адольфо Гарсия-Састре
Дмитрий Замарин
Светлана Садекова
Рейчел Эллисон Алтура
Юэн Пхан
Брайан Б. Хейнз
Джедд Д. Волчок
Original Assignee
Икан Скул Оф Медсин Эт Маунт Синай
Мемориал Слоан Кеттеринг Кэнсер Сентер
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Икан Скул Оф Медсин Эт Маунт Синай, Мемориал Слоан Кеттеринг Кэнсер Сентер, Мерк Шарп И Доум Корп. filed Critical Икан Скул Оф Медсин Эт Маунт Синай
Priority claimed from PCT/US2018/032255 external-priority patent/WO2018209194A2/en
Publication of EA201992687A1 publication Critical patent/EA201992687A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В настоящем документе описаны химерные вирусы болезни Ньюкасла, содержащие упакованный геном, содержащий трансген, кодирующий интерлейкин-12. Химерные вирусы болезни Ньюкасла и их композиции могут быть использованы в сочетании с антагонистом белка программируемой клеточной гибели 1 ("PD-1") или его лиганда в лечении рака. В частности, в настоящем документе описаны способы лечения рака, включающие введение химерных вирусов болезни Ньюкасла в сочетании с антагонистом PD-1 или его лиганда, при этом химерный вирус болезни Ньюкасла содержит упакованный геном, содержащий трансген, кодирующий интерлейкин-12.This document describes chimeric viruses of Newcastle disease containing a packaged genome containing a transgene encoding interleukin-12. Chimeric Newcastle disease viruses and their compositions can be used in combination with a programmed cell death protein antagonist 1 ("PD-1") or its ligand in the treatment of cancer. In particular, methods for treating cancer are described herein comprising administering chimeric Newcastle disease viruses in combination with a PD-1 antagonist or ligand thereof, wherein the Newcastle chimeric virus virus contains a packaged gene containing a transgene encoding interleukin-12.

EA201992687A 2017-05-17 2018-05-11 NEWcastle Disease VIRUSES AND THEIR APPLICATION EA201992687A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762507690P 2017-05-17 2017-05-17
PCT/US2018/032255 WO2018209194A2 (en) 2017-05-12 2018-05-11 Newcastle disease viruses and uses thereof

Publications (1)

Publication Number Publication Date
EA201992687A1 true EA201992687A1 (en) 2020-03-26

Family

ID=69942866

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992687A EA201992687A1 (en) 2017-05-17 2018-05-11 NEWcastle Disease VIRUSES AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201992687A1 (en)

Similar Documents

Publication Publication Date Title
PH12019550229A1 (en) Newcastle disease viruses and uses thereof
SA520412637B1 (en) Oncolytic adenovirus encoding a b7 protein
MD4655C1 (en) Newcastle disease viruses and uses thereof
EA201890278A1 (en) ANTIBODIES TO PD-L1
EA202090739A1 (en) PROTEINS BINDING ANTIGEN OF MATURING B-CELLS
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
EA201691487A1 (en) HUMAN ANTIBODIES TO PD-L1
CY1121873T1 (en) TREATMENT OF CANCER
MY181106A (en) Anti-lag3 antibodies and uses thereof
EA202090124A1 (en) ADENOVIRUS ARMED WITH A BISPECIFIC T-CELL RECRUITER (BITE)
EA201892648A1 (en) PICHINDE VIRUSES WITH THREE-SEGMENTED GENOM AS VECTOR VECTIONS
CY1123697T1 (en) TREATMENT OF AMD USING THE AAV2 VARIANT WITH AFLIVERCEPT
EA201700181A1 (en) COMPOSITIONS OF ADENOSINDEMINASE-2 (ADA-2), THEIR OPTIONS AND METHODS OF USE
MA39390A1 (en) Gene therapy for the treatment of retinitis pigmentosa
EA201891399A1 (en) BIPIRAZOLE DERIVATIVES, SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MX2019004029A (en) Compounds and methods for diagnosis and treatment of viral infections.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201992687A1 (en) NEWcastle Disease VIRUSES AND THEIR APPLICATION
EA202092487A1 (en) HUMAN KINURENINASE ENZYMES AND THEIR APPLICATION
EA201992587A1 (en) PEPTIDES AND THEIR APPLICATION AS ANTIVIRAL AGENTS
AR117809A2 (en) NEWCASTLE DISEASE VIRUS AND ITS USES
EA201691777A1 (en) CONTAINING CYANOGRUPE COMPOUNDS AZABENZOFURANE FOR THE TREATMENT OF HEPATITIS C
EA201791442A1 (en) METHODS OF TREATMENT OF HEMATOLOGICAL DISTURBANCES, SOLID TUMORS OR INFECTIOUS DISEASES WITH THE USE OF NATURAL CELL-CALLERS
EA201890595A1 (en) ONCOLYTIC ADENOVIRUS, ENCODING B7 PROTEIN
MY185846A (en) Oncolytic adenovirus encoding a b7 protein